With 14 initial public offerings (IPO) on the calendar for last week, it was almost inevitable that some would fall by the wayside. As it turns out only 8 made the leap onto the public markets, with 3 biotechs delaying a week and three other companies either postponing or withdrawing their planned IPOs.

The most newsworthy of last week’s IPOs were Bojangles’ Inc. (NASDAQ: BOJA) and Tallgrass Energy GP LP (NYS: TEGP). Bojangles’ got a first-day pop of 25% on Friday and Tallgrass got a 9% first-day pop on Thursday. Both IPOs priced above their expected range and sold more shares. The Tallgrass IPO was the largest by a U.S.-based company to date in 2015.

In the week ahead there are 6 companies making a new run at an IPO and three holdovers from last week. The coming week’s largest IPO is another midstream energy company general partner.

IPO ETF manager Renaissance Capital reported that 57 IPOs have priced in the U.S. so far this year, down 45% from a year ago. Total proceeds raised through May 8th equaled $9.8 billion, down 51% compared with the same period in 2014. Of the 57 IPOs that have gone off this year, 28 have come from the healthcare sector. Last year’s IPO total came in at $85.2 billion, the highest total in the past ten years. Renaissance Capital does not include “best efforts” or blank check companies in its totals.

Here are the 9 IPOs scheduled for the week beginning May 11th:

Gelesis Inc., a holdover from last week, is biotech firm products to induce weight loss and improve glycemic control in overweight and obese patients, including pre-diabetes and type 2 diabetes patients. The company plans to offer 4 million shares in an expected price range of $12 to $14 at a market cap of around $179 million. Joint bookrunners for the offering are Piper Jaffray, Stifel, and Guggenheim Securities. The first trading date is indicated only as “day-to-day” and shares will trade  on the Nasdaq under the ticker symbol GLSS.

Another holdover, MultiVir Inc., is a clinical-stage gene therapy company developing a pipeline of products for the treatment of multiple oncological indications. The company plans to offer 4.6 million shares in an expected price range of $12 to $14, raising about $60 million at a market cap of $193 million. Sole bookrunner for the offering is RBC Capital Markets, and co-managers include Nomura Securities, Cantor Fitzgerald, and LifeSci Capital. The first trading date is indicated only as “Week of May 12th” and shares will trade  on the Nasdaq under the ticker symbol MVIR.

The third holdover from last week is Anterios Inc., a clinical stage biopharmaceutical company focused on the development, manufacturing, and commercialization of novel botulinum products for therapeutic and aesthetic applications. The company plans to offer 3.9 million shares in an expected price range of $12 to $14 to raise about $51 million at a market cap of $175.5 million. Joint bookrunners are Stifel and RBC Capital Markets. Co-managers are JMP Securities and Needham & Co. The initial trading date is indicated only as “day-to-day” and shares will trade on the Nasdaq under the ticker symbol ANTE.

EQT GP Holdings LP is a limited partnership that will own 21.3 million limited partner units in EQT Corp. (NYSE: EQM), 1.24 million general partner units representing the 2% general partner interest in EQT Corp., and all of the general partner’s incentive distribution rights. EQT Corp. operates in the Marcellus shale region. The company plans to offer 20 million limited partnership units in an expected IPO price range of $21 to $24 to raise $450 million at a market cap of nearly $6 billion. Joint bookrunners for the offering include Barclays, Goldman Sachs, BofA/Merrill Lynch, Citi, Credit Suisse, Deutsche Bank, J.P. Morgan, RBC Capital Markets, and Wells Fargo Securities. Co-managers include Mitsubishi UFJ Securities, BNP Paribas, PNC Capital Markets, Scotiabank/Howard Weil, Suntrust Robinson Humphrey, Ladenburg Thalmann & Co., Oppenheimer & Co., and U.S. Capital Advisors. Common units are expected to price Monday and begin trading Tuesday on the New York Stock Exchange under the ticker symbol EQGP.

Arcadia Biosciences Inc. is an agricultural biotechnology trait development company. The company plans to offer 7.2 million shares in an IPO price range of $13 to $15 to raise about $100 million at a market cap of $532 million. Joint bookrunners for the IPO are Credit Suisse, J.P. Morgan, and Piper Jaffray. Shares are expected to price Tuesday and begin trading Wednesday on the Nasdaq under the ticker symbol RKDA.

Jaguar Animal Health Inc. develops and commercializes gastrointestinal products for companion and production animals. The company plans to offer 3.2 million shares at $7, raising $22.1 million at a market cap of about $59 million. Jaguar postponed an offering schedule for last November that was intended to raise $40 million at a market cap of $86 million. Sole bookrunner for this offering is Aegis Capital Corp. Co-managers are CRT Capital Group and Feltl and Co. The IPO is set to begin trading Wednesday on the Nasdaq under the ticker symbol JAGX.

Fenix Parts Inc. recycles and resells OEM automotive parts. The company plans to offer 11 million shares in an expected price range of $9 to $11, raising $110 million at a market cap of around $166 million. Joint bookrunners for the offering are BMO Capital Markets and Stifel. Co-Managers are BB&T Capital Markets and Barrington Research. Shares are expected to price Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol FENX.

Fortress Transportation and Infrastructure Investors Ltd. acquires and owns high-quality transportation and related infrastructure assets worldwide. The company plans to offer 20 million shares in at IPO price range of $19 to $21 to raise $400 million at a market cap of $1.47 billion. The company filed confidentially with the SEC in October 2013 according to Renaissance Capital. Joint bookrunners for the offering include Citi, BofA/Merrill Lynch, Barclays, Deutsche Bank, and UBS Investment Bank. Co-managers include JMP Securities, Stephens Inc., and Wolfe Research Securities. Shares are expected to price Wednesday and begin trading Thursday on the New York Stock Exchange under the ticker symbol FTAI.
Galapagos NV is Belgium-based clinical stage biotechnology company specializing in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. The company is already listed on the Euronext exchanges in Brussels and Amsterdam under the ticker symbol GLPG and over-the-counter in the U.S. under the symbol GLPYY. The company plans to sell 3.8 million American Depositary Shares (ADS) at $42.43 per ADS. Each ADS is worth one ordinary share. Underwriters for the offering include Morgan Stanley, Credit Suisse, and Cowen & Co. Co-managers are Nomura Securities and Bryan Garnier & Co. ADSes are expected to price Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol GLPG.

ALSO READ: Companies with the Best (and Worst) Reputations

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.